See more : Star Diamond Corporation (SHGDF) Income Statement Analysis – Financial Results
Complete financial analysis of Biora Therapeutics, Inc. (BIOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biora Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Maiden Forgings Limited (MAIDEN.BO) Income Statement Analysis – Financial Results
- Indergiri Finance Limited (INDERGR.BO) Income Statement Analysis – Financial Results
- Turbogen Ltd (TURB.TA) Income Statement Analysis – Financial Results
- Kaya Holdings, Inc. (KAYS) Income Statement Analysis – Financial Results
- B2Holding ASA (B2H.OL) Income Statement Analysis – Financial Results
Biora Therapeutics, Inc. (BIOR)
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 4.00K | 305.00K | 1.25M | 74.31M | 143.99M | 127.97M |
| Cost of Revenue | 0.00 | 907.00K | 1.44M | 93.43M | 100.49M | 92.08M |
| Gross Profit | 4.00K | -602.00K | -190.00K | -19.12M | 43.49M | 35.90M |
| Gross Profit Ratio | 100.00% | -197.38% | -15.24% | -25.73% | 30.21% | 28.05% |
| Research & Development | 29.84M | 24.05M | 45.79M | 47.74M | 63.40M | 48.71M |
| General & Administrative | 0.00 | 0.00 | 68.54M | 75.44M | 61.32M | 51.24M |
| Selling & Marketing | 0.00 | 0.00 | 4.76M | 52.89M | 58.89M | 50.19M |
| SG&A | 37.31M | 38.04M | 73.30M | 128.33M | 120.21M | 101.43M |
| Other Expenses | 0.00 | 2.62M | 5.99M | -25.08M | 0.00 | 0.00 |
| Operating Expenses | 67.15M | 62.09M | 119.08M | 176.07M | 183.61M | 150.14M |
| Cost & Expenses | 67.15M | 62.09M | 119.08M | 269.50M | 284.10M | 242.21M |
| Interest Income | 0.00 | 10.99M | 12.64M | 9.92M | 575.00K | 1.80M |
| Interest Expense | 9.82M | 10.99M | 12.64M | 34.87M | 9.20M | 9.09M |
| Depreciation & Amortization | 555.00K | 907.00K | 1.44M | 1.44M | 4.60M | 4.60M |
| EBITDA | -114.05M | -37.35M | -164.57M | -106.18M | -135.44M | -110.17M |
| EBITDA Ratio | -2,851,350.00% | -19,398.03% | -5,106.66% | -262.66% | -92.51% | -84.93% |
| Operating Income | -67.14M | -61.78M | -117.84M | -195.19M | -140.12M | -114.24M |
| Operating Income Ratio | -1,678,575.00% | -20,256.07% | -9,449.64% | -262.66% | -97.31% | -89.27% |
| Total Other Income/Expenses | -57.28M | 12.53M | -60.80M | -35.00M | -8.62M | -9.62M |
| Income Before Tax | -124.42M | -49.25M | -178.64M | -230.06M | -148.74M | -123.86M |
| Income Before Tax Ratio | -3,110,600.00% | -16,147.54% | -14,325.58% | -309.58% | -103.30% | -96.78% |
| Income Tax Expense | -90.00K | -420.00K | -119.00K | -37.53M | -706.00K | 5.25M |
| Net Income | -124.12M | -48.83M | -178.52M | -192.53M | -148.04M | -129.11M |
| Net Income Ratio | -3,102,875.00% | -16,009.84% | -14,316.04% | -259.08% | -102.81% | -100.88% |
| EPS | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
| EPS Diluted | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
| Weighted Avg Shares Out | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
| Weighted Avg Shares Out (Dil) | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
Biora Therapeutics, Inc. (BIOR) Q3 2023 Earnings Call Transcript
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biora Therapeutics, Inc. - BIOR
Biora Therapeutics Submits Updated IND Application for BT-600
Biora Therapeutics to Submit Updated IND Application for BT-600
Source: https://incomestatements.info
Category: Stock Reports